Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Gross Margin: 2020-2025

Historic Gross Margin for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Sep 2025 value amounting to 80.80%.

  • Mirum Pharmaceuticals' Gross Margin rose 382.00% to 80.80% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.92%, marking a year-over-year increase of 724.00%. This contributed to the annual value of 75.77% for FY2024, which is 100.00% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Gross Margin stood at 80.80%, which was down 1.07% from 81.67% recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Gross Margin ranged from a high of 100.00% in Q1 2021 and a low of 64.03% during Q4 2023.
  • Its 3-year average for Gross Margin is 77.53%, with a median of 78.57% in 2023.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Gross Margin slumped by 3,597bps in 2023, and later soared by 1,306bps in 2024.
  • Mirum Pharmaceuticals' Gross Margin (Quarterly) stood at 100.00% in 2021, then remained steady at 100.00% in 2022, then tumbled by 3,597bps to 64.03% in 2023, then spiked by 1,306bps to 77.09% in 2024, then skyrocketed by 382bps to 80.80% in 2025.
  • Its Gross Margin stands at 80.80% for Q3 2025, versus 81.67% for Q2 2025 and 79.37% for Q1 2025.